e-learning
resources
Paris 2018
Sunday, 16.09.2018
New developments in the treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma
M. Carlsson (Mölndal, Sweden), M. Braddock (Cambridge, United Kingdom), Y. Li (Gaithersburg, United States of America), J. Wang (Gaithersburg, United States of America), W. Xu (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America)
Source:
International Congress 2018 – New developments in the treatment of asthma
Session:
New developments in the treatment of asthma
Session type:
Thematic Poster
Number:
1034
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Carlsson (Mölndal, Sweden), M. Braddock (Cambridge, United Kingdom), Y. Li (Gaithersburg, United States of America), J. Wang (Gaithersburg, United States of America), W. Xu (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America). No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma. 1034
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001
A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients
Source: Eur Respir J, 58 (6) 2101702; 10.1183/13993003.01702-2021
Year: 2021
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
COPD treatment from pathophysiology to clinical trials
Source: ERS Live 2007
Year: 2007
Asthma and allergic rhinitis - clinical presentation of effects different types of drugs
Source: Eur Respir J 2005; 26: Suppl. 49, 506s
Year: 2005
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
Source: International Congress 2017 – Asthma management
Year: 2017
Heterogeneity of treatment response in bronchiectasis clinical trials
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Variability and lack of predictive ability of asthma end-points in clinical trials
Source: Eur Respir J 2002; 20: 1102-1109
Year: 2002
Measuring bronchodilation in COPD clinical trials
Source: Eur Respir J 2004; 24: Suppl. 48, 122s
Year: 2004
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma
Source: Eur Respir J, 51 (1) 1701126; 10.1183/13993003.01126-2017
Year: 2018
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept